In a filing, Adc Therapeutics SA revealed its Director Azelby Robert unloaded Company’s shares for reported $20216.0 on Jun 17 ’24. In the deal valued at $2.89 per share,6,995 shares were sold. As a result of this transaction, Azelby Robert now holds 53,005 shares worth roughly $0.14 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, BIZZARI JEAN-PIERRE sold 6,995 shares, generating $20,216 in total proceeds. Upon selling the shares at $2.89, the Director now owns 79,502 shares.
Before that, Sandor Victor sold 6,995 shares. Adc Therapeutics SA shares valued at $20,216 were divested by the Director at a price of $2.89 per share. As a result of the transaction, Sandor Victor now holds 80,886 shares, worth roughly $0.21 million.
Cantor Fitzgerald initiated its Adc Therapeutics SA [ADCT] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. JP Morgan also remained covering ADCT and has increased its forecast on August 10, 2023 with a “Neutral” recommendation from previously “an Underweight” rating. BofA Securities revised its rating on April 24, 2023. It rated ADCT as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ADCT
On Tuesday, Adc Therapeutics SA [NYSE:ADCT] saw its stock fall -5.20% to $2.55. Over the last five days, the stock has lost -9.57%. Adc Therapeutics SA shares have risen nearly 53.61% since the year began. Nevertheless, the stocks have risen 24.39% over the past one year. While a 52-week high of $6.04 was reached on 02/20/24, a 52-week low of $0.36 was recorded on 01/04/24. SMA at 50 days reached $3.90, while 200 days put it at $2.69. A total of 0.61 million shares were traded, compared to the trading of 0.39 million shares in the previous session.
Levels Of Support And Resistance For ADCT Stock
The 24-hour chart illustrates a support level at 2.49, which if violated will result in even more drops to 2.43. On the upside, there is a resistance level at 2.65. A further resistance level may holdings at 2.75. The Relative Strength Index (RSI) on the 14-day chart is 28.26, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.44, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.33%. Stochastics %K at 3.61% indicates the stock is a buying.
The most recent change occurred on December 06, 2022 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $12 price target.
